Trials / Unknown
UnknownNCT04682314
B-Cell Reconstitution After Hematopoietic Stem Cell Transplantation
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 60 (estimated)
- Sponsor
- Assistance Publique - Hôpitaux de Paris · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a potentially curative treatment for a variety of hematological malignancies. However, patients who have received this treatment have a persistent deficit in humoral immunity up to one year post-transplant. To date, the design of new therapeutic strategies to improve immune recovery in allo-HSCT patients is still hampered by the fact that post-transplant regenerative hematopoiesis has never been studied, and more generally by our currently limited knowledge on the development and function of human B lymphocytes. The main objective of our study is to study early B-cell progenitor reconstitution after allogeneic hematopoietic stem cell transplantation.
Conditions
Timeline
- Start date
- 2020-12-01
- Primary completion
- 2023-03-01
- Completion
- 2023-07-01
- First posted
- 2020-12-23
- Last updated
- 2020-12-23
Source: ClinicalTrials.gov record NCT04682314. Inclusion in this directory is not an endorsement.